Patterson-UTI Energy Swings to Q4 Net Loss, Revenue Declines-February 2024-www.financetom.com

Patterson-UTI Energy Swings to Q4 Net Loss, Revenue Declines

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Patterson-UTI Energy Swings to Q4 Net Loss, Revenue Declines

Feb 6, 2025 1:16 AM

03:48 AM EST, 02/06/2025 (MT Newswires) -- Patterson-UTI Energy ( PTEN ) reported a Q4 net loss Wednesday of $0.13 per diluted share, swinging from earnings of $0.15 a year earlier.

Analysts polled by FactSet expected a loss of $0.10.

Revenue for the quarter ended Dec. 31 was $1.16 billion, down from $1.58 billion a year earlier.

Analysts surveyed by FactSet expected $1.24 billion.

Previous page： Hershey Likely to Post Strong Quarterly Results But Tariffs Expected to Weigh on Guidance, RBC Says Next page： Lexaria Bioscience Says Drug Delivery Technology Reduces GLP-1 Drug Side Effects in Trial

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Hershey Likely to Post Strong Quarterly Results But Tariffs Expected to Weigh on Guidance, RBC Says

Jul 28, 2025

10:39 AM EDT, 07/28/2025 (MT Newswires) -- Hershey (HSY) is expected to report second-quarter results above market expectations amid strong consumption trends, but tariff-related pressures could force the chocolate manufacturer to adjust its earnings outlook downward for the ongoing three-month period, RBC Capital Markets said in a Monday client note. The brokerage's scanner data for the second quarter suggests that...

Lexaria Bioscience Says Drug Delivery Technology Reduces GLP-1 Drug Side Effects in Trial

Jul 28, 2025

10:37 AM EDT, 07/28/2025 (MT Newswires) -- Lexaria Bioscience ( LEXX ) said Monday its phase 1b trial of DehydraTECH oral drug delivery technology showed that it reduced overall side effects by 36.5% compared with the Rybelsus control arm. The eight-week trial also showed that the drug delivery technology reduced gastrointestinal side effects by 43.5% compared with the control arm,...

Google agrees $36 million fine for anti-competitive deals with Australia telcos

Aug 17, 2025

SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...

Pollard Banknote Up Near 2% As Says Secured License to Supply Gaming-Related Goods and Services in the United Arab Emirates

Jul 28, 2025

10:37 AM EDT, 07/28/2025 (MT Newswires) -- Pollard Banknote Limited ( PBKOF ) was at last look up near 2% on Monday after saying that it has been approved as a licensed gaming-related vendor by the General Commercial Gaming Regulatory Authority. The license authorizes the company to provide gaming-related goods and services and reflects its interest in supporting regulated lottery...